A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Early Parkinson's Disease Clinical Trial

Official title:
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa

Status Completed

Clinical Trial Summary

To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00537485
Study type	Interventional
Source	Otsuka Pharmaceutical Co., Ltd.
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	September 2007
Completion date	December 2009

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04269642` - SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease	Phase 2
	Completed	`NCT03329508` - A Phase 3 Study With P2B001 in Subjects With Early Parkinson's	Phase 3